Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06251310 · ClinicalTrials.gov registry record · Phase 1

SW-682 in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Mesothelioma, Malignant, sponsored by SpringWorks Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
186
Enrollment target
8
Study locations

NCT06251310 is a Phase 1 study of Advanced Solid Tumor and Mesothelioma, Malignant that is actively recruiting participants, run by SpringWorks Therapeutics. The registered enrollment target is 186 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 8 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06251310, a Phase 1 study of Advanced Solid Tumor and Mesothelioma, Malignant, is actively recruiting participants, sponsored by SpringWorks Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
186 participants
Enrollment target
8
Study locations

Study Summary

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.

Conditions Studied

Advanced Solid Tumor Mesothelioma, Malignant

Interventions

  • DRUG SW-682
  • DRUG Combination Therapy

Study Locations (8)

California

  • UC San Diego Moores Cancer Center - La Jolla
  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • SpringWorks Clinical Trial Site - Los Angeles

Texas

  • Mary Crowley Cancer Research - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston

Arizona

  • SpringWorks Clinical Trial Site - Scottsdale

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Oregon

  • Knight Cancer Institute Clinical Trials - Portland

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2024-07-30
Est. Completion 2030-06
Phase Phase 1

Sponsor

SpringWorks Therapeutics

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06251310

The ClinicalTrials.gov registry entry for NCT06251310 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is SpringWorks Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which SW-682 is the first listed.

NCT06251310 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT06251310 about?

NCT06251310 is a clinical study titled "SW-682 in Advanced Solid Tumors". This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after ap...

What is the current status of trial NCT06251310?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2024-07-30. Estimated completion is 2030-06.

What conditions does trial NCT06251310 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Mesothelioma, Malignant.

What interventions are being tested in trial NCT06251310?

The interventions under investigation include: SW-682 (DRUG), Combination Therapy (DRUG).

Who is sponsoring clinical trial NCT06251310?

This trial is sponsored by SpringWorks Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06251310 being conducted?

This trial has 8 study locations across Arizona, California, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Mesothelioma, Malignant

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.